Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead-A Systematic Review

Int J Mol Sci. 2022 Nov 15;23(22):14117. doi: 10.3390/ijms232214117.

Abstract

Hepatocellular carcinoma (HCC) remains one of the most common malignancies and the third cause of cancer-related death worldwide, with surgery being the best prognostic tool. Among the well-known causative factors of HCC are chronic liver virus infections, chronic virus hepatitis B (HBV) and chronic hepatitis virus C (HCV), aflatoxins, tobacco consumption, and non-alcoholic liver disease (NAFLD). There is a need for the development of efficient molecular markers and alternative therapeutic targets of great significance. In this review, we describe the general characteristics of HCC and present a variety of targeted therapies that resulted in progress in HCC therapy.

Keywords: cancer; carcinoma; hepatocarcinogenesis; hepatocellular; targeted; therapy.

Publication types

  • Systematic Review
  • Review

MeSH terms

  • Carcinoma, Hepatocellular* / drug therapy
  • Carcinoma, Hepatocellular* / etiology
  • Hepacivirus
  • Hepatitis B, Chronic* / complications
  • Hepatitis C, Chronic* / complications
  • Humans
  • Liver Neoplasms* / pathology

Grants and funding

This research received no external funding.